FDA
approval
· 2019-05-02
FDA Approved: KUVAN — Supplemental Application (BioMarin Pharmaceutical Inc.)
Summary
FDA approved BioMarin's supplemental application for KUVAN (sapropterin dihydrochloride) submitted by BioMarin Pharmaceutical Inc.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
SUPPL AP for KUVAN (SAPROPTERIN DIHYDROCHLORIDE)